{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:25:11Z","timestamp":1751534711359},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"AstraZeneca, Malaysia"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jdiacomp.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T15:44:12Z","timestamp":1476805452000},"page":"494-503","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype"],"prefix":"10.1016","volume":"31","author":[{"given":"Lee Ling","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Tong Boon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viraj","family":"Rajadhyaksha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siew Pheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0005","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. diabetes care, 1999\u20132010","volume":"368","author":"Ali","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdi.12453","article-title":"Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period","volume":"7","author":"Araki","year":"2016","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/dom.12464","article-title":"Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus","volume":"17","author":"Araki","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","article-title":"Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: A randomized double-blind placebo-controlled 102-week trial","volume":"32","author":"Bailey","year":"2015","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0030","series-title":"Poster 1166 P","article-title":"Dapagliflozin in patients with type 2 diabetes and mixed dyslipidemia","author":"Bays","year":"2016"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0091","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.5888\/pcd12.150006","article-title":"Disparities in age at diabetes diagnosis among Asian Americans: implications for early preventive measures","volume":"12","author":"Becerra","year":"2015","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104weeks in patients aged 55-80years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0045","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0050","author":"Canagliflozin prescribing information"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0055","author":"CANVAS study group"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0060","author":"CANVAS-R study group"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0065","first-page":"44","article-title":"The Asian diabetes phenotypes: Challenges and opportunities","volume":"59","author":"Chan","year":"2014","journal-title":"Diabetes Voice"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0070","doi-asserted-by":"crossref","first-page":"f5446","DOI":"10.1136\/bmj.f5446","article-title":"Association between body mass index and cardiovascular disease mortality in East Asians and South Asians: Pooled analysis of prospective data from the Asia cohort consortium","volume":"347","author":"Chen","year":"2013","journal-title":"BMJ"},{"issue":"Suppl. 2","key":"10.1016\/j.jdiacomp.2016.10.008_bb0075","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1007\/PL00002944","article-title":"Vascular disease prevalence in diabetic patients in China: Standardised comparison with the 14 centres in the WHO multinational study of vascular disease in diabetes","volume":"44","author":"Chi","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0080","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2337\/dc10-2300","article-title":"Deriving ethnic-specific BMI cutoff points for assessing diabetes risk","volume":"34","author":"Chiu","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0085","doi-asserted-by":"crossref","first-page":"e1000236","DOI":"10.1371\/journal.pmed.1000236","article-title":"Event rates, hospital utilization, and costs associated with major complications of diabetes: A multicountry comparative analysis","volume":"7","author":"Clarke","year":"2010","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0090","author":"Dapagliflozin FDA prescribing information"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0095","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/sj.ki.5000326","article-title":"Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL","volume":"69","author":"de Zeeuw","year":"2006","journal-title":"Kidney International"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-Year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0105","author":"DELIGHT study group"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0110","author":"DERIVE study group"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1467-789X.2002.00065.x","article-title":"Asians are different from Caucasians and from each other in their body mass index\/body fat per cent relationship","volume":"3","author":"Deurenberg","year":"2002","journal-title":"Obesity Reviews"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0120","series-title":"Diabetes atlas","year":"2015"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1758-5996-3-12","article-title":"Visceral adiposity, insulin resistance and cancer risk","volume":"3","author":"Donohoe","year":"2011","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0130","author":"Empagliflozin FDA prescribing information"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0135","author":"European Medicine Agency"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","article-title":"Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus","volume":"14","author":"Fioretto","year":"2015","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.12214","article-title":"Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action","volume":"5","author":"Fugita","year":"2014","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0155","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.metabol.2004.02.012","article-title":"Insulin secretion and insulin sensitivity at different stages of glucose tolerance: A cross-sectional study of Japanese type 2 diabetes","volume":"53","author":"Fukushima","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0160","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/jcm4101866","article-title":"Nephroprotection by hypoglycemic agents: Do we have supporting data?","volume":"4","author":"G\u00f3rriz","year":"2015","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0165","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/nutd.2014.40","article-title":"Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin","volume":"4","author":"Haas","year":"2014","journal-title":"Nutrition & Diabetes"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0170","doi-asserted-by":"crossref","first-page":"P142","DOI":"10.1055\/s-0034-1374999","article-title":"Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): Pooled data from four pivotal phase III trials","volume":"9","author":"Hach","year":"2014","journal-title":"Diabetologie und Stoffwechsel"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0175","author":"Hong Kong reference framework for diabetes care for adults in primary care settings"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2016.10.008_bb0180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1467-789X.2007.00439.x","article-title":"Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension","volume":"9","author":"Huxley","year":"2008","journal-title":"Obesity Reviews"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jdi.12266","article-title":"Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study","volume":"6","author":"Inagaki","year":"2015","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0190","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/14656566.2014.935764","article-title":"Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: A 24-week, randomized, double-blind, placebo-controlled, phase III study","volume":"15","author":"Inagaki","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of Hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0200","author":"Japanese Diabetes Society"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0205","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","article-title":"Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: A randomized, blinded, prospective phase III study","volume":"36","author":"Ji","year":"2014","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A randomized, 12-week, double-blind, placebo-controlled, phase II trial","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0215","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12325-015-0198-0","article-title":"Efficacy and safety of empagliflozin monotherapy for 52weeks in Japanese patients with type 2 diabetes: A randomized, double-blind, parallel-group study","volume":"32","author":"Kadowaki","year":"2015","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0220","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.12325","article-title":"Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise","volume":"16","author":"Kaku","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s13300-014-0086-7","article-title":"Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: An open-label study","volume":"5","author":"Kaku","year":"2014","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0230","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/dom.12047","article-title":"Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: A phase II multicentre, randomized, double-blind, placebo-controlled trial","volume":"15","author":"Kaku","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0235","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/dom.12403","volume":"17","author":"Kashiwagi","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0240","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc12-1235","article-title":"Ethnic differences in the relationship between insulin sensitivity and insulin response: A systematic review and meta-analysis","volume":"36","author":"Kodama","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0245","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney International"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0250","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrendo.2013.102","article-title":"Diabetes and its comorbidities\u2014Where east meets west","volume":"9","author":"Kong","year":"2013","journal-title":"Nature Reviews. Endocrinology"},{"issue":"Suppl. 2","key":"10.1016\/j.jdiacomp.2016.10.008_bb0255","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1007\/PL00002943","article-title":"Vascular disease in younger-onset diabetes: Comparison of European, Asian and American Indian cohorts of the WHO multinational study of vascular disease in diabetes","volume":"44","author":"Lee","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: Similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0265","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/(SICI)1096-9136(199801)15:1<53::AID-DIA521>3.0.CO;2-V","article-title":"Mortality and morbidity from diabetes in South Asians and Europeans: 11-Year follow-up of the Southall diabetes survey, London, UK","volume":"15","author":"Mather","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0270","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves beta cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.10.008_bb0275","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI2415","article-title":"Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus","volume":"102","author":"Meyer","year":"1998","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0280","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1210\/jc.2014-1724","article-title":"Ethnic differences in insulin sensitivity, beta-cell function, and hepatic extraction between Japanese and Caucasians: A minimal model analysis","volume":"99","author":"M\u00f8ller","year":"2014","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0285","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2337\/dc13-0598","article-title":"Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians","volume":"37","author":"M\u00f8ller","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0290","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.12327","article-title":"Durability of glycaemic efficacy over 2years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin","volume":"16","author":"Nauck","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(15)00336-8","article-title":"10-year trajectory of \u03b2-cell function and insulin sensitivity in the development of type 2 diabetes: A community-based prospective cohort study","volume":"4","author":"Ohn","year":"2016","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0300","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2337\/diacare.20.11.1664","article-title":"Prevalence of diabetes and its risk factors in China, 1994","volume":"20","author":"Pan","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0305","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/dc10-0811","article-title":"Effect of intrauterine diabetes exposure on the incidence of end-stage renal disease in young adults with type 2 diabetes","volume":"33","author":"Pavkov","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0310","author":"Pharmaceuticals and Medical Devices Agency, Japan"},{"issue":"12","key":"10.1016\/j.jdiacomp.2016.10.008_bb0315","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0320","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2458-13-386","article-title":"Diabetes in the workplace\u2014Diabetic's perceptions and experiences of managing their disease at work: A qualitative study","volume":"13","author":"Ruston","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0325","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2337\/dc06-0003","article-title":"South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients","volume":"29","author":"Shaw","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0330","first-page":"1979","article-title":"Clinical and pathophysiological features of Japanese patients with type 2 diabetes mellitus and their risk factors for diabetic complication","volume":"73","author":"Sone","year":"2015","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: A meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0340","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study","volume":"30","author":"Stenl\u00f6f","year":"2014","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0345","author":"US Food and Drug Administration"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0350","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.10.008_bb0355","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12649","article-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia","volume":"18","author":"Wan Seman","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0360","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0365","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0370","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin","volume":"156","author":"Wilding","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0375","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0380","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2013.168118","article-title":"Prevalence and control of diabetes in Chinese adults","volume":"310","author":"Xu","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0385","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11892-015-0602-9","article-title":"\u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians","volume":"15","author":"Yabe","year":"2015","journal-title":"Current Diabetes Reports"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0390","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial","author":"Yang","year":"2016","journal-title":"Journal of Diabetes"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0395","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","article-title":"Prevalence of diabetes among men and women in China","volume":"362","author":"Yang","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0400","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-8587(14)70137-8","article-title":"Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): A cross-sectional study of a prospective cohort","volume":"2","author":"Yeung","year":"2014","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0405","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12699","article-title":"Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: Pooled data from four phase III trials","author":"Yoon","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.10.008_bb0410","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England Journal of Medicine"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716303865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716303865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T13:22:31Z","timestamp":1536326551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716303865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1056872716303865"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.10.008","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}